Domantis Limited

Bristol-myers Squibb Compnay

Agenus Inc.

Bristol Meyers Squibb Company

Olga Ignatovich

Suzanne J Suchard

Steven G Nadler

Steve Holmes

Aaron Paul Yamniuk

Steven Grant

James William Bryson

James K Tamura

Robert P Rehfuss

Laura Price

Anish Suri

Philip Drew

Christopher Plummer

Murray McKinnon

Brendan Classon

Steve Grant

Benjamin Maxime Morin

Dhan Sidhartha Chand

Nicholas Stuart Wilson

Emmanuel Cyrille Pascal Briend

Marc A Van Dijk

Dennis John Underwood

David Adam Savitsky

Cornelia Anne Mundt

Mark Arthur Findeis

Yanping Xiao

K Mark Bushell

Nicola Anne Ramsay

Spencer Campbell

Ian M Tomlinson

Oliver Schon

Jeremy Dale Waight

Rudolf M T De Wildt

Shawn Michael Jennings

Greg Winter

Randi Barbara Gombos

Zahra Jawad

Beth Wensley

Veronica Franciszka Ilkow

Roland Beckmann

Murray Mckinnon

Neil Brewis

Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.

Compositions monovalent for CD28 binding and methods of use

The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.

Anti-TIGIT and anti-CD96 antibodies

The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGF&#x3b2;-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Anti-CD73 antibodies and methods of use thereof

The instant disclosure provides antibodies that specifically bind to CD96 (e.g., human CD96) and antagonize CD96 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Antibodies that specifically bind human CD96

The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Anti-CD137 antibodies and methods of use thereof

Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single Vor Vdomain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

Antibody polypeptides that antagonize CD40L

Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40L

Nucleic acids encoding antibody polypeptides that antagonize CD40L

Growing community of inventors

Cambridge, United Kingdom

Olga Ignatovich